Cervical Dystonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major cervical dystonia markets reached a value of US$ 148.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 270.0 Million by 2034, exhibiting a growth rate (CAGR) of 5.61% during 2024-2034.
The cervical dystonia market has been comprehensively analyzed in IMARC's new report titled "Cervical Dystonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cervical dystonia, which is also known as spasmodic torticollis, refers to a neurological disorder that causes involuntary muscle contractions in the neck, leading to aberrant movements and postures of the neck and head. Depending on the causative factor, cervical dystonia is classified as primary (idiopathic) and secondary (symptomatic). The symptoms of this disease can range from mild to severe. Some common indications include head twisting in various directions, jerking motion of the head, chin towards the shoulder, neck pain extending to the shoulders, etc. Additionally, individuals suffering from the ailment may experience disabling pain, fatigue, a raised shoulder, hand tremors, enlargement of the neck muscle, headaches, etc. The diagnosis of the condition is based on a review of the patient's clinical features, medical history, and physical exam. The healthcare provider may also perform several diagnostic tests and procedures, such as blood workups, magnetic resonance imaging (MRI), electromyography (EMG), etc., to confirm a diagnosis and dismiss other possible causes of underlying symptoms.
The rising prevalence of neurological disorders, which cause abnormalities in the basal ganglia or other brain areas that control body movement, is primarily driving the cervical dystonia market. In addition to this, the increasing incidence of various risk factors, including advancing age, head or neck trauma, family history of dystonia, genetic mutations, etc., is also bolstering the market growth. Moreover, the widespread adoption of effective medications, such as anticholinergics, GABAergics, anticonvulsants, dopaminergics, etc., to treat disease symptoms is acting as another significant growth-inducing factor. Apart from this, the inflating application of biofeedback therapy, which helps improve mind-body connection and relax muscles to regulate involuntary body processes, is also propelling the market growth. Additionally, multiple key players are making extensive investments in R&D activities to launch new assessment tools with excellent sensitivity and specificity for early disease diagnosis. This, in turn, is creating a positive outlook for the market. Furthermore, the emerging popularity of deep brain stimulation for treating the ailment on account of its several associated benefits, such as reduced muscle contractions and long-lasting relief from symptoms, is expected to drive the cervical dystonia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the cervical dystonia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cervical dystonia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cervical dystonia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cervical dystonia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cervical dystonia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cervical dystonia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the cervical dystonia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cervical dystonia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cervical dystonia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cervical dystonia across the seven major markets?
What is the number of prevalent cases (2018-2034) of cervical dystonia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cervical dystonia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with cervical dystonia across the seven major markets?
What is the size of the cervical dystonia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cervical dystonia?
What will be the growth rate of patients across the seven major markets?
Cervical Dystonia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cervical dystonia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cervical dystonia market?
What are the key regulatory events related to the cervical dystonia market?
What is the structure of clinical trial landscape by status related to the cervical dystonia market?
What is the structure of clinical trial landscape by phase related to the cervical dystonia market?
What is the structure of clinical trial landscape by route of administration related to the cervical dystonia market?
The cervical dystonia market has been comprehensively analyzed in IMARC's new report titled "Cervical Dystonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cervical dystonia, which is also known as spasmodic torticollis, refers to a neurological disorder that causes involuntary muscle contractions in the neck, leading to aberrant movements and postures of the neck and head. Depending on the causative factor, cervical dystonia is classified as primary (idiopathic) and secondary (symptomatic). The symptoms of this disease can range from mild to severe. Some common indications include head twisting in various directions, jerking motion of the head, chin towards the shoulder, neck pain extending to the shoulders, etc. Additionally, individuals suffering from the ailment may experience disabling pain, fatigue, a raised shoulder, hand tremors, enlargement of the neck muscle, headaches, etc. The diagnosis of the condition is based on a review of the patient's clinical features, medical history, and physical exam. The healthcare provider may also perform several diagnostic tests and procedures, such as blood workups, magnetic resonance imaging (MRI), electromyography (EMG), etc., to confirm a diagnosis and dismiss other possible causes of underlying symptoms.
The rising prevalence of neurological disorders, which cause abnormalities in the basal ganglia or other brain areas that control body movement, is primarily driving the cervical dystonia market. In addition to this, the increasing incidence of various risk factors, including advancing age, head or neck trauma, family history of dystonia, genetic mutations, etc., is also bolstering the market growth. Moreover, the widespread adoption of effective medications, such as anticholinergics, GABAergics, anticonvulsants, dopaminergics, etc., to treat disease symptoms is acting as another significant growth-inducing factor. Apart from this, the inflating application of biofeedback therapy, which helps improve mind-body connection and relax muscles to regulate involuntary body processes, is also propelling the market growth. Additionally, multiple key players are making extensive investments in R&D activities to launch new assessment tools with excellent sensitivity and specificity for early disease diagnosis. This, in turn, is creating a positive outlook for the market. Furthermore, the emerging popularity of deep brain stimulation for treating the ailment on account of its several associated benefits, such as reduced muscle contractions and long-lasting relief from symptoms, is expected to drive the cervical dystonia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the cervical dystonia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cervical dystonia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cervical dystonia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cervical dystonia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cervical dystonia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cervical dystonia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the cervical dystonia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cervical dystonia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cervical dystonia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cervical dystonia across the seven major markets?
What is the number of prevalent cases (2018-2034) of cervical dystonia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cervical dystonia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with cervical dystonia across the seven major markets?
What is the size of the cervical dystonia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cervical dystonia?
What will be the growth rate of patients across the seven major markets?
Cervical Dystonia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cervical dystonia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cervical dystonia market?
What are the key regulatory events related to the cervical dystonia market?
What is the structure of clinical trial landscape by status related to the cervical dystonia market?
What is the structure of clinical trial landscape by phase related to the cervical dystonia market?
What is the structure of clinical trial landscape by route of administration related to the cervical dystonia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CERVICAL DYSTONIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CERVICAL DYSTONIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CERVICAL DYSTONIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CERVICAL DYSTONIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CERVICAL DYSTONIA - UNMET NEEDS
10 CERVICAL DYSTONIA - KEY ENDPOINTS OF TREATMENT
11 CERVICAL DYSTONIA - MARKETED PRODUCTS
11.1 List of Cervical Dystonia Marketed Drugs Across the Top 7 Markets
11.1.1 Myobloc (Botulinum toxin B) - Supernus Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Xeomin (Botulinum toxin A) - Merz Pharma
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Botox (Onabotulinum toxin A) - AbbVie
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Dysport (Botulinum toxin A) - Ipsen
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CERVICAL DYSTONIA - PIPELINE DRUGS
12.1 List of Cervical Dystonia Pipeline Drugs Across the Top 7 Markets
12.1.1 DaxibotulinumtoxinA - Revance Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 ABP - 450 - Daewoong Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CERVICAL DYSTONIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CERVICAL DYSTONIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CERVICAL DYSTONIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cervical Dystonia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cervical Dystonia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cervical Dystonia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cervical Dystonia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cervical Dystonia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cervical Dystonia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cervical Dystonia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cervical Dystonia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cervical Dystonia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cervical Dystonia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cervical Dystonia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cervical Dystonia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cervical Dystonia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cervical Dystonia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cervical Dystonia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cervical Dystonia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cervical Dystonia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cervical Dystonia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cervical Dystonia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cervical Dystonia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cervical Dystonia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cervical Dystonia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cervical Dystonia - Access and Reimbursement Overview
16 CERVICAL DYSTONIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CERVICAL DYSTONIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CERVICAL DYSTONIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CERVICAL DYSTONIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CERVICAL DYSTONIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CERVICAL DYSTONIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CERVICAL DYSTONIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CERVICAL DYSTONIA - UNMET NEEDS
10 CERVICAL DYSTONIA - KEY ENDPOINTS OF TREATMENT
11 CERVICAL DYSTONIA - MARKETED PRODUCTS
11.1 List of Cervical Dystonia Marketed Drugs Across the Top 7 Markets
11.1.1 Myobloc (Botulinum toxin B) - Supernus Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Xeomin (Botulinum toxin A) - Merz Pharma
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Botox (Onabotulinum toxin A) - AbbVie
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Dysport (Botulinum toxin A) - Ipsen
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CERVICAL DYSTONIA - PIPELINE DRUGS
12.1 List of Cervical Dystonia Pipeline Drugs Across the Top 7 Markets
12.1.1 DaxibotulinumtoxinA - Revance Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 ABP - 450 - Daewoong Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CERVICAL DYSTONIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CERVICAL DYSTONIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CERVICAL DYSTONIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cervical Dystonia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cervical Dystonia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cervical Dystonia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cervical Dystonia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cervical Dystonia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cervical Dystonia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cervical Dystonia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cervical Dystonia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cervical Dystonia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cervical Dystonia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cervical Dystonia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cervical Dystonia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cervical Dystonia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cervical Dystonia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cervical Dystonia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cervical Dystonia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cervical Dystonia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cervical Dystonia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cervical Dystonia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cervical Dystonia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cervical Dystonia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cervical Dystonia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cervical Dystonia - Access and Reimbursement Overview
16 CERVICAL DYSTONIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CERVICAL DYSTONIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CERVICAL DYSTONIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
